Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease

Circulation: Cardiovascular Imaging

Volumn 3, Issue 6, 2010, Pages 727-734

  Broberg, Craig S ^a   Chugh, Sumeet S ^a   Conklin, Catherine ^b   Sahn, David J ^a   Jerosch Herold, Michael ^b,c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cyanosis; Endomyocardial fibrosis; Gadolinium; Heart defects, congenital; Heart failure; Ventricular dysfunction

Indexed keywords

GADODIAMIDE;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYANOSIS; DISEASE ASSOCIATION; FALLOT TETRALOGY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN SATURATION; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HEART DEFECTS, CONGENITAL; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; VENTRICULAR DYSFUNCTION;

EID: 78650298735     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.108.842096     Document Type: Article

References (44)

1. Bolger AP, Coats AJ, Gatzoulis MA. Congenital heart disease: the original heart failure syndrome. Eur Heart J. 2003;24:970-976.
2. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007;115:163-172.
3. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JI, Somerville J, Williams RG, Webb GD. Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol. 2001;37: 1170-1175.
4. Nieminen HP, Jokinen EV, Sairanen HI. Causes of late deaths after pediatric cardiac surgery: a population-based study. J Am Coll Cardiol. 2007;50:1263-1271.
5. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83: 1849-1865.
6. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol. 2002;34: 1577-1584.
7. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB, Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007;50:591-596.
8. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940-2945.
9. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110: 558-565.
10. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304-310.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
12. Anand K, Mooss AN, Mohiuddin SM. Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. J Renin Angiotensin Aldosterone Syst. 2006;7:15-19.
13. McIntosh HD, Cohen AI. Pulmonary stenosis: the importance of the myocardial factor in determining the clinical course and surgical results. Am Heart J. 1963;65:715-716.
14. Jones M, Ferrans VJ, Morrow AG, Roberts WC. Ultrastructure of crista supraventricularis muscle in patients with congenital heart diseases associated with right ventricular outflow tract obstruction. Circulation. 1975; 51:39-67.
15. Jones M, Ferrans VJ. Myocardial degeneration in congenital heart disease. Comparison of morphologic findings in young and old patients with congenital heart disease associated with muscular obstruction to right ventricular outflow. Am J Cardiol. 1977;39:1051-1063.
16. Jones M, Ferrans VJ. Myocardial ultrastructure in children and adults with congenital heart disease. Cardiovasc Clin. 1979;10:501-530.
17. Chowdhury UK, Sathia S, Ray R, Singh R, Pradeep KK, Venugopal P. Histopathology of the right ventricular outflow tract and its relationship to clinical outcomes and arrhythmias in patients with tetralogy of Fallot. J Thorac Cardiovasc Surg. 2006;132:270-277.
18. Babu-Narayan SV, Goktekin O, Moon JC, Broberg CS, Pantely GA, Pennell DJ, Gatzoulis MA, Kilner PJ. Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation. 2005;111:2091-2098.
19. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, Khan M, Ho SY, Pennell DJ, Gatzoulis MA. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation. 2006;113:405-413.
20. Broberg CS, Prasad SK, Gatzoulis MA. The interventricular relationship with Eisenmenger syndrome: findings with cardiac magnetic resonance and late gadolinium enhancement [abstract]. J Am Coll Cardiol. 2007; 49:263A.
21. Oosterhof T, Mulder BJ, Vliegen HW, de Roos A. Corrected tetralogy of Fallot: delayed enhancement in right ventricular outflow tract. Radiology. 2005;237:868-871.
22. Hartke LP, Gilkeson RC, O'Riordan MA, Siwik ES. Evaluation of right ventricular fibrosis in adult congenital heart disease using gadoliniumenhanced magnetic resonance imaging: initial experience in patients with right ventricular loading conditions. Congenit Heart Dis. 2006;1: 192-201.
23. Messroghli DR, Plein S, Higgins DM, Walters K, Jones TR, Ridgway JP, Sivananthan MU. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution-reproducibility study. Radiology. 2006;238:1004-1012.
24. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52: 141-146.
25. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta S, Kaye D, Taylor A. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580.
26. Pack NA, Dibella EV, Wilson BD, McGann CJ. Quantitative myocardial distribution volume from dynamic contrast-enhanced MRI. Magn Reson Imaging. 2008;26:532-542.
27. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;295:H1234-H1242.
28. Kehr E, Sono M, Chugh SS, Jerosch-Herold M. Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro. Int J Cardiovasc Imaging. 2008;24:61-68.
29. Look D, Locker D. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum. 1976;41:250-251.
30. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001;218:703-710.
31. Harris PA, Lorenz CH, Holburn GE, Overholser KA. Regional measurement of the Gd-DTPA tissue partition coefficient in canine myocardium. Magn Reson Med. 1997;38:541-545.
32. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD, Gatzoulis MA. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002; 106:92-99.
33. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828-835.
34. Friedrich M. There is more than shape and function. J Am Coll Cardiol. 2008;52:1581-1583.
35. Thornhill RE, Prato FS, Wisenberg G, Moran GR, Sykes J. Determining the extent to which delayed-enhancement images reflect the partitioncoefficient of Gd-DTPA in canine studies of reperfused and unreperfused myocardial infarction. Magn Reson Med. 2004;52:1069-1079.
36. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111:186-193.
37. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985.
38. Assomull RG, Pennell DJ, Prasad SK. Cardiovascular magnetic resonance in the evaluation of heart failure. Heart. 2007;93:985-992.
39. Jerosch-Herold M, Sheridan D, Kushner J, Nauman D, Burgess D, Dutton D, Hershberger R. Cardiac magnetic resonance contrast enhancement differentiates patients affected with familial dilated cardiomyopathy from asymptomatic relatives. J Cardiovasc Magn Reson. 2006;8:154-155.
40. Knauth AL, Gauvreau K, Powell AJ, Landzberg MJ, Walsh EP, Lock JE, del Nido PJ, Geva T. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart. 2008;94:211-216.
41. Geva T, Sandweiss BM, Gauvreau K, Lock JE, Powell AJ. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll Cardiol. 2004;43:1068-1074.
42. Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, Marcotte F, Mercier LA. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebocontrolled clinical trial. Circulation. 2005;112:2411-2416.
43. Vonder Muhll I, Liu P, Webb G. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease. Int J Cardiol. 2004;97(suppl 1): 25-33.
44. Babu-Narayan S, Uebing A, Davlouros PA, Path MK, Davidson S, Bayne S, Dimopoulos K, Pennell DJ, Gibson DG, Kilner PJ, Li W, Gatzoulis MA. Potential therapeutic role of ACE inhibitors in repaired tetralogy of Fallot and pulmonary regurgitation-the appropriate study (ACE inhibitors for potential prevention of the deleterious effects of pulmonary regurgitation in adults with repaired tetralogy of Fallot). Oral presentation to the International Symposium on Adult Congenital Heart Disease; June 5 2008; Toronto, CA.